[CAS NO. 108409-83-2] FH535

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [108409-83-2]

Catalog

SLK-S7484

Brand

Selleck

CAS

108409-83-2

DESCRIPTION [108409-83-2]

Overview

MDL	MFCD01212888
Molecular Weight	361.20
Molecular Formula	C13H10Cl2N2O4S
SMILES	O=S(C1=CC(Cl)=CC=C1Cl)(NC2=CC=C([N+]([O-])=O)C=C2C)=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.7685 mL	13.8427 mL	27.6855 mL
5 mM	0.5537 mL	2.7685 mL	5.5371 mL
10 mM	0.2769 mL	1.3843 mL	2.7685 mL
50 mM	0.0554 mL	0.2769 mL	0.5537 mL

Description

FH535 is a signaling inhibitor and also a dual and antagonist.

Targets

Wnt/β-catenin ^[1]

PPARγ ^[1]

PPARδ ^[1]

In vitro

FH535 antagonizes β-Catenin/Tcf–mediated transcription, and inhibits recruitment of the coactivators GRIP1 and β-catenin to PPARδ and PPARγ. FH535 shows selective anti-proliferation effect on some cancer cells expressing high or active Wnt/β-catenin pathway. FH535 increases cigarette smoke condensate cytotoxicity, and causes changes in β-catenin and EGR-1 signaling. FH535 has potential therapeutic value in treatment of liver cancer by targeting liver cancer stem cells and hepatocellular carcinoma cell lines.

References

[1] Handeli S, et al. Mol Cancer Ther. 2008, 7(3), 521-529.
[2] Polk WW. Int J Toxicol. 2012, 31(4), 380-389.
[3] Gedaly R, et al. PLoS One. 2014, 9(6), e99272.